Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...

Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

Samsung Biologics spins off Samsung Bioepis Holdings to enhance competitiveness Samsung Bioepis Holdings aims to streamline ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

Samsung Biologics, a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar ...

The US biotech – currently in the throes of a major restructuring drive under new ... of a potential sale to longstanding partner Samsung Bioepis and a bid from Indian drugmaker Intas.

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...

Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by ...